Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung CancerGiorgio V. Scagliotti, Nasser H. Hanna, José Rodrigues Pereira et al.|Journal of Clinical Oncology|2010Cited by 454
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung CancerPrimo N. Lara, Giorgio V. Scagliotti, Jean‐Yves Douillard et al.|Journal of Clinical Oncology|2011Cited by 320